2007 1. Adamek, A., et al., High dose aspirin and left ventricular ...

2007
1. Adamek, A., et al., High dose aspirin and left ventricular remodeling after
myocardial infarction: aspirin and myocardial infarction. Basic Res Cardiol, 2007.
102(4): p. 334-40.
2. Adamek, A., et al., Role of 5-lipoxygenase in myocardial ischemia-reperfusion
injury in mice. Eur J Pharmacol, 2007. 571(1): p. 51-4.
3. Allolio, B., W. Arlt, and S. Hahner, DHEA: why, when, and how much--DHEA
replacement in adrenal insufficiency. Ann Endocrinol (Paris), 2007. 68(4): p. 268-
73.
4. Angermann, C.E., et al., Rationale and design of a randomised, controlled,
multicenter trial investigating the effects of selective serotonin re-uptake inhibition
on morbidity, mortality and mood in depressed heart failure patients (MOOD-HF).
Eur J Heart Fail, 2007. 9(12): p. 1212-22.
5. Arias-Loza, P.A., et al., Both estrogen receptor subtypes, alpha and beta,
attenuate cardiovascular remodeling in aldosterone salt-treated rats.
Hypertension, 2007. 50(2): p. 432-8.
6. Bauersachs, J., et al., HMG CoA reductase inhibition and left ventricular mass in
hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study. Eur J
Clin Invest, 2007. 37(11): p. 852-9.
7. Bauersachs, J. and T. Thum, MicroRNAs in the broken heart. Eur J Clin Invest,
2007. 37(11): p. 829-33.
8. Bauersachs, J. and T. Thum, Endothelial progenitor cell dysfunction:
mechanisms and therapeutic approaches. Eur J Clin Invest, 2007. 37(8): p. 603-
6.
9. Bausch, B., et al., Germline NF1 mutational spectra and loss-of-heterozygosity
analyses in patients with pheochromocytoma and neurofibromatosis type 1. J
Clin Endocrinol Metab, 2007. 92(7): p. 2784-92.
10. Beer, M., et al., Energetic differences between viable and non-viable myocardium
in patients with recent myocardial infarction are not an effect of differences in wall
thinning- a multivoxel (31)P-MR-spectroscopy and MRI study. Eur Radiol, 2007.
17(5): p. 1275-83.
11. Beer, S., et al., High-dose 17beta-estradiol treatment prevents development of
heart failure post-myocardial infarction in the rat. Basic Res Cardiol, 2007.
102(1): p. 9-18.
12. Bijnens, B., et al., Investigating cardiac function using motion and deformation
analysis in the setting of coronary artery disease. Circulation, 2007. 116(21): p.
2453-64.
13. Burkard, N., et al., Conditional neuronal nitric oxide synthase overexpression
impairs myocardial contractility. Circ Res, 2007. 100(3): p. e32-44.
14. Chobanyan, K., et al., GC-MS assay for hepatic DDAH activity in diabetic and
non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric
dimethylarginine (ADMA): evaluation of the importance of S-nitrosothiols as
inhibitors of DDAH activity in vitro and in vivo in humans. J Chromatogr B Analyt
Technol Biomed Life Sci, 2007. 858(1-2): p. 32-41.
15. Claus, P., et al., Mechanisms of postsystolic thickening in ischemic myocardium:

mathematical modelling and comparison with experimental ischemic substrates.
Ultrasound Med Biol, 2007. 33(12): p. 1963-70.
16. Eng, C.M., et al., Fabry disease: baseline medical characteristics of a cohort of
1765 males and females in the Fabry Registry. J Inherit Metab Dis, 2007. 30(2):
p. 184-92.
17. Ertl, G. and C.E. Angermann, [Therapy of chronic left heart failure]. Internist
(Berl), 2007. 48(1): p. 59-65; quiz 66-7.
18. Faller, H., et al., Depression and survival in chronic heart failure: does gender
play a role Eur J Heart Fail, 2007. 9(10): p. 1018-23.
19. Faller, H., et al., Is health-related quality of life an independent predictor of
survival in patients with chronic heart failure J Psychosom Res, 2007. 63(5): p.
533-8.
20. Fouque, D., et al., EBPG guideline on nutrition. Nephrol Dial Transplant, 2007.
22 Suppl 2: p. ii45-87.
21. Frantz, S., et al., Role of p38 mitogen-activated protein kinase in cardiac
remodelling. Br J Pharmacol, 2007. 150(2): p. 130-5.
22. Frantz, S., G. Ertl, and J. Bauersachs, Mechanisms of disease: Toll-like
receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med, 2007. 4(8):
p. 444-54.
23. Frantz, S., et al., Detrimental effects of testosterone on post-myocardial infarction
remodelling in female rats. J Physiol Pharmacol, 2007. 58(4): p. 717-27.
24. Frantz, S., et al., Tissue-specific effects of the nuclear factor kappaB subunit p50
on myocardial ischemia-reperfusion injury. Am J Pathol, 2007. 171(2): p. 507-12.
25. Frydrychowicz, A., et al., Functional assessment of isolated right heart failure by
high resolution in-vivo cardiovascular magnetic resonance in mice. J Cardiovasc
Magn Reson, 2007. 9(3): p. 623-7.
26. Guder, G., et al., Complementary and incremental mortality risk prediction by
cortisol and aldosterone in chronic heart failure. Circulation, 2007. 115(13): p.
1754-61.
27. Hahner, S. and B. Allolio, Do dehydroepiandrosterone supplements have antiaging
potential Nat Clin Pract Urol, 2007. 4(6): p. 302-3.
28. Hahner, S., et al., Impaired subjective health status in 256 patients with adrenal
insufficiency on standard therapy based on cross-sectional analysis. J Clin
Endocrinol Metab, 2007. 92(10): p. 3912-22.
29. Hansen-Hagge, T.E., et al., Transmission of oxLDL-derived lipid peroxide
radicals into membranes of vascular cells is the main inducer of oxLDL-mediated
oxidative stress. Atherosclerosis, 2008. 197(2): p. 602-11.
30. Hocher, B., et al., Soluble CD154 is a unique predictor of nonfatal and fatal
atherothrombotic events in patients who have end-stage renal disease and are
on hemodialysis. J Am Soc Nephrol, 2007. 18(4): p. 1323-30.
31. Hofmann, U., et al., The proinflammatory cytokines TNF-alpha and IL-1 beta
impair economy of contraction in human myocardium. Cytokine, 2007. 39(3): p.
157-62.
32. Holdaas, H., et al., The effect of fluvastatin on cardiac outcomes in patients with
moderate to severe renal insufficiency: a pooled analysis of double-blind,
randomized trials. Int J Cardiol, 2007. 117(1): p. 64-74.

33. Jager, K.J., et al., The valuable contribution of observational studies to
nephrology. Kidney Int, 2007. 72(6): p. 671-5.
34. Johanssen, S. and B. Allolio, Mifepristone (RU 486) in Cushing's syndrome. Eur
J Endocrinol, 2007. 157(5): p. 561-9.
35. Kielstein, J.T., K. Sydow, and T. Thum, Tilarginine in patients with acute
myocardial infarction and cardiogenic shock. Jama, 2007. 298(9): p. 971; author
reply 972-3.
36. Knaus, A., et al., Direct inhibition of cardiac hyperpolarization-activated cyclic
nucleotide-gated pacemaker channels by clonidine. Circulation, 2007. 115(7): p.
872-80.
37. Kooman, J., et al., EBPG guideline on haemodynamic instability. Nephrol Dial
Transplant, 2007. 22 Suppl 2: p. ii22-44.
38. Krane, V., et al., Dialyzer membrane characteristics and outcome of patients with
type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis, 2007. 49(2): p.
267-75.
39. Krane, V. and C. Wanner, Dyslipidaemia in chronic kidney disease. Minerva Urol
Nefrol, 2007. 59(3): p. 299-316.
40. Krieter, D.H., et al., Effects of a polyelectrolyte additive on the selective dialysis
membrane permeability for low-molecular-weight proteins. Nephrol Dial
Transplant, 2007. 22(2): p. 491-9.
41. Lichtenauer, U.D., et al., Pre-B-cell transcription factor 1 and steroidogenic factor
1 synergistically regulate adrenocortical growth and steroidogenesis.
Endocrinology, 2007. 148(2): p. 693-704.
42. Lohila, A., et al., Micrometeorological measurements of methane and carbon
dioxide fluxes at a municipal landfill. Environ Sci Technol, 2007. 41(8): p. 2717-
22.
43. Lopau, K., A. Greser, and C. Wanner, Efficacy and safety of preemptive anti-
CMV therapy with valganciclovir after kidney transplantation. Clin Transplant,
2007. 21(1): p. 80-5.
44. Lopez-Santiago, L.F., et al., Sodium channel Scn1b null mice exhibit prolonged
QT and RR intervals. J Mol Cell Cardiol, 2007. 43(5): p. 636-47.
45. Marz, W., et al., N-terminal pro-B-type natriuretic peptide predicts total and
cardiovascular mortality in individuals with or without stable coronary artery
disease: the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem,
2007. 53(6): p. 1075-83.
46. Merkle, S., et al., A role for caspase-1 in heart failure. Circ Res, 2007. 100(5): p.
645-53.
47. Monks, D., et al., [Phenotyping of type 2 diabetes mellitus by "genetic field work":
are data sufficient that are based only on a questionnaire]. Dtsch Med
Wochenschr, 2007. 132(37): p. 1875-9.
48. Muellenbach, R.M., et al., High-frequency oscillatory ventilation reduces lung
inflammation: a large-animal 24-h model of respiratory distress. Intensive Care
Med, 2007. 33(8): p. 1423-33.
49. Nair, S., et al., Vaccination against the forkhead family transcription factor Foxp3
enhances tumor immunity. Cancer Res, 2007. 67(1): p. 371-80.
50. Nikolaev, V.O., et al., A novel fluorescence method for the rapid detection of

functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll
Cardiol, 2007. 50(5): p. 423-31.
51. Quaschning, T., et al., Lack of endothelial nitric oxide synthase promotes
endothelin-induced hypertension: lessons from endothelin-1
transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol,
2007. 18(3): p. 730-40.
52. Rubenwolf, P., et al., [Antiphospholipid antibody syndrome: a priori a
contraindication to kidney transplantation]. Aktuelle Urol, 2007. 38(2): p. 132-6.
53. Sartorio, C.L., et al., Mineralocorticoid receptor blockade improves vasomotor
dysfunction and vascular oxidative stress early after myocardial infarction.
Hypertension, 2007. 50(5): p. 919-25.
54. Schafer, A., et al., Late thrombosis of a drug-eluting stent during combined antiplatelet
therapy in a clopidogrel nonresponsive diabetic patient: shall we routinely
test platelet function Thromb Haemost, 2007. 97(5): p. 862-5.
55. Schafer, A., M. Eigenthaler, and J. Bauersachs, Severe neutropenia under
clopidogrel treatment three weeks after coronary stenting. Thromb Haemost,
2007. 97(2): p. 317-8.
56. Schafer, A., et al., Telmisartan improves vascular function and reduces platelet
activation in rats with streptozotocin-induced diabetes mellitus. Pharmacol Res,
2007. 56(3): p. 217-23.
57. Schafer, A., et al., Improved endothelial function and reduced platelet activation
by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with
streptozotocin-induced diabetes mellitus. Biochem Pharmacol, 2007. 73(9): p.
1367-75.
58. Schafer, A., et al., The CX3C chemokine fractalkine induces vascular dysfunction
by generation of superoxide anions. Arterioscler Thromb Vasc Biol, 2007. 27(1):
p. 55-62.
59. Schneider, R., et al., Downregulation of organic anion transporters OAT1 and
OAT3 correlates with impaired secretion of para-aminohippurate after ischemic
acute renal failure in rats. Am J Physiol Renal Physiol, 2007. 292(5): p. F1599-
605.
60. Schulz, C., et al., Chemokine fractalkine mediates leukocyte recruitment to
inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin
expressed on activated platelets. Circulation, 2007. 116(7): p. 764-73.
61. Schwedler, S.B., et al., Native C-reactive protein induces endothelial dysfunction
in ApoE-/- mice: implications for iNOS and reactive oxygen species.
Atherosclerosis, 2007. 195(2): p. e76-84.
62. Stel, V.S., et al., The randomized clinical trial: an unbeatable standard in clinical
research Kidney Int, 2007. 72(5): p. 539-42.
63. Stork, S., et al., Low levels of adiponectin predict worsening of arterial
morphology and function. Atherosclerosis, 2007. 194(2): p. e147-53.
64. Strotmann, J., et al., Progression of Fabry cardiomyopathy. Clin Ther, 2007. 29
Suppl A: p. S13-4.
65. Tattersall, J., et al., EBPG guideline on dialysis strategies. Nephrol Dial
Transplant, 2007. 22 Suppl 2: p. ii5-21.
66. Terzolo, M., et al., Adjuvant mitotane treatment for adrenocortical carcinoma. N

Engl J Med, 2007. 356(23): p. 2372-80.
67. Thum, T. and S.D. Anker, Nutritional iron deficiency in patients with chronic
illnesses. Lancet, 2007. 370(9603): p. 1906.
68. Thum, T. and J. Bauersachs, Microarray-based gene expression profiling to
elucidate cellular responses to nitric oxide--a review from an analytical and
biomedical point of view. J Chromatogr B Analyt Technol Biomed Life Sci, 2007.
851(1-2): p. 3-11.
69. Thum, T., et al., Growth hormone treatment improves markers of systemic nitric
oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab, 2007.
92(11): p. 4172-9.
70. Thum, T., et al., Endothelial nitric oxide synthase uncoupling impairs endothelial
progenitor cell mobilization and function in diabetes. Diabetes, 2007. 56(3): p.
666-74.
71. Thum, T., et al., Differential effects of organic nitrates on endothelial progenitor
cells are determined by oxidative stress. Arterioscler Thromb Vasc Biol, 2007.
27(4): p. 748-54.
72. Thum, T., et al., MicroRNAs in the human heart: a clue to fetal gene
reprogramming in heart failure. Circulation, 2007. 116(3): p. 258-67.
73. Thum, T., et al., Age-dependent impairment of endothelial progenitor cells is
corrected by growth-hormone-mediated increase of insulin-like growth-factor-1.
Circ Res, 2007. 100(3): p. 434-43.
74. To, T.T., et al., Pituitary-interrenal interaction in zebrafish interrenal organ
development. Mol Endocrinol, 2007. 21(2): p. 472-85.
75. Tordoir, J., et al., EBPG on Vascular Access. Nephrol Dial Transplant, 2007. 22
Suppl 2: p. ii88-117.
76. Tripepi, G., et al., Measures of effect: relative risks, odds ratios, risk difference,
and 'number needed to treat'. Kidney Int, 2007. 72(7): p. 789-91.
77. Tsikas, D., et al., Accurate quantification of dimethylamine (DMA) in human urine
by gas chromatography-mass spectrometry as pentafluorobenzamide derivative:
evaluation of the relationship between DMA and its precursor asymmetric
dimethylarginine (ADMA) in health and disease. J Chromatogr B Analyt Technol
Biomed Life Sci, 2007. 851(1-2): p. 229-39.
78. von Eynatten, M., et al., Retinol-binding protein 4 is associated with components
of the metabolic syndrome, but not with insulin resistance, in men with type 2
diabetes or coronary artery disease. Diabetologia, 2007. 50(9): p. 1930-7.
79. Wagner, J.A., et al., Natriuretic peptides and myocardial oxygen supply-todemand
ratio in patients with aortic stenosis. Eur J Clin Invest, 2007. 37(6): p.
463-71.
80. Wanner, C., Fabry disease model: a rational approach to the management of
Fabry disease. Clin Ther, 2007. 29 Suppl A: p. S2-5.
81. Wanner, C., On statin treatment to prevent sepsis in dialysis patients. Am J
Kidney Dis, 2007. 50(5): p. 700-2.
82. Wanner, C., Fabry disease: clinical outcomes of agalsidase enzyme replacement
therapies. Int J Clin Pract, 2007. 61(7): p. 1234-5; author reply 1235.
83. Wanner, C. and F. Breunig, Fabry nephropathy and the case for adjunctive renal
therapy. J Am Soc Nephrol, 2007. 18(9): p. 2426-8.

84. Wanner, C., C. Drechsler, and V. Krane, Lipid metabolism in chronic kidney
disease: the role of statins in cardiovascular risk. J Ren Nutr, 2007. 17(1): p. 75-
8.
85. Weidemann, F., et al., Assessment of the contractile reserve in patients with
intermediate coronary lesions: a strain rate imaging study validated by invasive
myocardial fractional flow reserve. Eur Heart J, 2007. 28(12): p. 1425-32.
86. Weidemann, F., et al., A new echocardiographic approach for the detection of
non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J, 2007. 28(24): p.
3020-6.
87. Weidemann, F., J.M. Strotmann, and B. Bijnens, Letter by Weidemann et al
regarding article, "Global diastolic strain rate for the assessment of left ventricular
relaxation and filling pressure". Circulation, 2007. 116(14): p. e368; author reply
e369.
88. Weininger, M., et al., Multi-slice cardiac computed tomography reveals
anomalous origin of the right coronary artery between the great arteries. Int J
Cardiol, 2007. 119(3): p. e77-8.
89. Widder, J.D., et al., Regulation of tetrahydrobiopterin biosynthesis by shear
stress. Circ Res, 2007. 101(8): p. 830-8.
90. Widder, J.D., et al., Role of the multidrug resistance protein-1 in hypertension
and vascular dysfunction caused by angiotensin II. Arterioscler Thromb Vasc
Biol, 2007. 27(4): p. 762-8.
91. Ziener, C.H., et al., Local frequency density of states around field
inhomogeneities in magnetic resonance imaging: effects of diffusion. Phys Rev E
Stat Nonlin Soft Matter Phys, 2007. 76(3 Pt 1): p. 031915.
92. Ziener, C.H., et al., Scaling laws for transverse relaxation times. J Magn Reson,
2007. 184(1): p. 169-75.